Call Us: 1.800.873.5297

By

Actos® Lawsuit Update: Philadelphia Jury Returns $2.3 Million Verdict In Favor of the Plaintiff

Bloomberg reports that a Philadelphia jury has returned a $2.3 million verdict in favor of the plaintiff after finding that the diabetes drug Actos® had been a significant cause of the plaintiff’s bladder cancer. The case is Kristufek v. Takeda Pharmaceuticals America Inc., Philadelphia Court of Common Pleas, Case ID 120702275. The jury also found that […]

By

Research Reveals Big Pharmaceutical Companies Spending More on Sales and Marketing than Research and Development

According to the Washington Post, a study conducted by the healthcare research firm GlobalData revealed that nine out of ten big pharmaceutical companies are spending more on sales and marketing than research and development (R&D). Johnson & Johnson, the biggest spender, expended roughly $17.5 billion dollars on sales and marketing in 2013, compared with $8.2 billion […]

By

AstraZeneca Pays $7.9 Million for Alleged Violations of Anti-Kickback Laws

The Wall Street Journal reports that the drug manufacturer, AstraZeneca, will pay $7.9 million to the federal government over allegations that the manufacturer violated anti-kickback laws and attempted to defraud the federal, state, and local U.S. governments. The drugmaker is accused of paying kickbacks to a large Pharmacy Benefits Manager in exchange for a guarantee that […]

By

Xarelto® Lawsuit Update: Roger C. Denton of Schlichter, Bogard & Denton, LLP Appointed to Plaintiffs’ Steering Committee

On February 9, 2015 the Honorable Eldon Fallon, sitting in the U.S. District Court for the Eastern District of Louisiana, appointed Roger C. Denton of Schlichter, Bogard & Denton, LLP to the Plaintiffs’ Steering Committee (PSC) in the national Xarelto® Multidistrict Litigation (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:14-md-02592, MDL 2592, Pretrial […]

By

Federal Judge Orders Permanent Injunction against Certain Medical Device Manufacturers

The FDA reports  that a Federal Judge sitting in the U.S. District Court of New Hampshire entered a consent decree of permanent injunction against four medical device manufacturing companies and two company officers. Between 2009 and 2013, the U.S. Food and Drug Administration (FDA) conducted ten inspections across the manufacturing sites. Inspections revealed multiple and […]

By

Alere INRatio® Test Strips, Monitor System Recalled

If you have been taking a blood-thinning drug (such as warfarin/Coumadin) or have been receiving heparin injections, you should be aware of an urgent recall of INRatio® PT/INR test strips and monitors. These products are used to test a patient’s INR (international normalized ratio) when taking warfarin and other anticoagulation medications. The goal with warfarin […]

By

Johnson & Johnson Faces Trial in Risperdal® Breast-Development Case

Johnson & Johnson (J&J) will face trial to defend itself against claims that its antipsychotic drug, Risperdal®, causes gynecomastia, a condition that causes young boys and males to grow breasts. The lawsuit, brought in the Philadelphia Court of Common Pleas, involves a boy who ingested Risperdal®  at the age of 8 and subsequently suffered from […]

By

Pfizer Agrees to $400 Million Settlement in Class-Action Securities Lawsuit Involving Investors

The Wall Street Journal reports that Pfizer has agreed to pay $400 million to settle a class-action securities lawsuit alleging that the company illegally marketed several medications causing its investors to lose money, according to a filing with the United States Securities and Exchange Commission (SEC). The securities lawsuit alleged that Pfizer marketed several drugs […]

By

Effexor Plaintiffs Seek to Drop 40% of Lawsuits from MDL

Law360 reports that the plaintiffs in a multidistrict litigation involving Effexor, a depression and anxiety medication manufactured by Wyeth Pharmaceuticals Inc., have sought to dismiss 26 lawsuits targeting the Pfizer unit over the drug’s alleged risk of birth defects. The multidistrict litigation is In re: Effexor (Venlafaxine Hydrochloride) Products Liability Litigation, MDL 2458. Judge Cynthia […]

By

According to Expert in Philadelphia State Court Case, Actos Largest Bladder Cancer Risk for Plaintiff

Law 360 reports that setting aside a history of smoking and other risk factors, an expert witness told a jury in Philadelphia that the most significant contributing factor for the retired western Pennsylvania teacher, who was diagnosed with bladder cancer in 2008, was his long-term Actos use. University of Colorado oncologist and bladder cancer specialist […]

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.